GrapheneDx
BOSTON and KNOXVILLE, Tenn.
GrapheneDx™, General Graphene Corporation and Sapphiros™ today announce a strategic partnership to industrialize graphene-based biosensors for medical devices used in point-of-care and consumer diagnostics for a variety of diseases.
GrapheneDx is an in vitro diagnostics company focused on advancing diagnostic capabilities at the point-of-care and consumer space. The company specializes in the functionalization of graphene to produce graphene field effect transistors (GFETs), which can be used as biosensors to detect diseases in biological samples. Graphene is a monatomic carbon sheet known for its impressive electrical properties that enable the detection of various biomolecules with great accuracy. GrapheneDx medical devices are designed to provide lab-grade accuracy, deliver results in less than 5 minutes, and are simple enough to perform both at the point-of-care and by patients themselves without the supervision of a healthcare professional* can become. The Company’s GFET platform is extremely versatile, demonstrating its performance in a wide variety of disease states (STIs, respiratory diseases, heart diseases, concussion and others) and sample types (stool, urine, swab, blood, etc.) with little or no sample preparation. In addition, the platform is capable of amplifying numerous analytes simultaneously from a single patient sample. GrapheneDx’s initial tests are designed to diagnose sexually transmitted infections, including chlamydia and gonorrhea, using a non-invasive, easy-to-collect urine sample.
“This strategic partnership highlights the core strengths of both partners and will enable GrapheneDx to bring affordable, accurate and timely diagnostics to patients around the world,” said Mike Musgnug, CEO of GrapheneDx Sapphiros to rapidly scale and commercialize our technology through the use of best-in-class tools, processes and expertise.”
General Graphene Corp, a leader in large-scale graphene manufacturing, will be the primary supplier of GrapheneDx for sheetlike chemical vapor deposition (CVD) graphene produced in a roll-to-roll format for use in EVM plant (Extreme Volume Manufacturing) will be supplied by Sapphiros. The General Graphene Corp. has an annual supply capacity of 100,000 square meters of graphene sheet. That’s more than any other graphene foundry and has qualities that can successfully fuel the development of rapid point-of-care medical diagnostic devices with lab-quality accuracy.
Greg Erickson, CEO of General Graphene, said, “We are the premier slab-based CVD graphene foundry and offer the scale and quality to support GrapheneDx’ plans for rapid growth of their impressive biosensor business.”
Sapphiros, a platform company dedicated to developing the next generation of consumption diagnostic technologies, will bring its expertise in Extreme Volume Manufacturing (EVM) and commercialization. Sapphiros operates its own industry-leading roll-to-roll EVM facility for point-of-care and consumer diagnostics with a capacity of 5 billion tests per year. EVM facility capabilities also include printed electronics and printed battery technology to enable cost-effective, single-use diagnostic testing with clear, easy-to-understand results. Sapphiros commercial department has extensive industry experience and relationships with the major distributors.
Mark Gladwell, CEO of Sapphiros added, “GrapheneDx is a diagnostics innovator with perhaps the most disruptive diagnostics platform we have ever seen. Combined with General Graphene’s impressive scale and graphene expertise, Sapphiros will accelerate the industrialization and commercialization of GrapheneDx’s biosensor technology.”
For more information, please contact Sapphiros at [email protected]
About GrapheneDx:
GrapheneDx is transforming diagnostics with a revolutionary graphene-based biosensor that puts high-performance diagnostics right in the hands of clinicians and consumers. GrapheneDx diagnostic tests provide results in less than 5 minutes for a wide range of indications using a variety of sample types.
About General Graphene Corporation:
General Graphene Corporation is a CVD-only graphene foundry that produces large-scale graphene by roll-to-roll (R2R) chemical vapor deposition (CVD). General Graphene, with its proprietary roll-to-roll CVD graphene manufacturing processes, is able to accelerate significant CVD graphene-based research and development at scale and accelerate the commercialization of CVD graphene materials in various markets.
About Sapphiros:
Sapphiros, backed by KKR and Neoenta, is a private consumer diagnostics company. Sapphiros’ portfolio of services and technologies includes novel sampling techniques, next-generation diagnostics, computational biology and printed electronics that make it easier for consumers worldwide to access critical diagnostic results. Knowing Now Moves Us™
*Product is under development. The claims made about these products have not been evaluated by the Food and Drug Administration.
Logo – https://mma.prnewswire.com/media/2092915/Enter_a_title_Logo.jpg
View original content:
Original content by: GrapheneDx, transmitted by news aktuell